Similar articles

• Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.

  Frembgen-Kesner T, Elcock AH. Frembgen-Kesner T, et al. J Mol Biol. 2006 May 26;359(1):202-14. doi: 10.1016/j.jmb.2006.03.021. Epub 2006 Mar 29. J Mol Biol. 2006. PMID: 16616932
• Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.

  Hammach A, Barbosa A, Gaenzler FC, Fadra T, Goldberg D, Hao MH, Kroe RR, Liu P, Qian KC, Ralph M, Sarko C, Soleymanzadeh F, Moss N. Hammach A, et al. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6316-20. doi: 10.1016/j.bmcl.2006.09.014. Epub 2006 Sep 28. Bioorg Med Chem Lett. 2006. PMID: 17010605
• Discovery and optimization of p38 inhibitors via computer-assisted drug design.

  Goldberg DR, Hao MH, Qian KC, Swinamer AD, Gao DA, Xiong Z, Sarko C, Berry A, Lord J, Magolda RL, Fadra T, Kroe RR, Kukulka A, Madwed JB, Martin L, Pargellis C, Skow D, Song JJ, Tan Z, Torcellini CA, Zimmitti CS, Yee NK, Moss N. Goldberg DR, et al. J Med Chem. 2007 Aug 23;50(17):4016-26. doi: 10.1021/jm070415w. Epub 2007 Jul 20. J Med Chem. 2007. PMID: 17658737
• Fragment-based drug discovery.

  Erlanson DA, McDowell RS, O'Brien T. Erlanson DA, et al. J Med Chem. 2004 Jul 1;47(14):3463-82. doi: 10.1021/jm040031v. J Med Chem. 2004. PMID: 15214773 Review. No abstract available.
• New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.

  Denise Martin E, De Nicola GF, Marber MS. Denise Martin E, et al. Circulation. 2012 Jul 17;126(3):357-68. doi: 10.1161/CIRCULATIONAHA.111.071886. Circulation. 2012. PMID: 22801653 Review. No abstract available.